Omeicos Ophthalmics Inc.

https://www.omeicos.com

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS’ technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Mueller and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). *

	Start	2018-04-01 established (approx)
	Group	Omeicos (Group)
	Industry	ophthalmic
	Person	Gebauer, Alexander (Omeicos 201804– Executive Board Member + CEO of Omeicos Ophthalmics before Sun Pharma + Ranbaxy)

	Region	Boston, MA
	Country	United States (USA)
	City	n. a. Boston, MA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Omeicos Therapeutics GmbH. (4/27/18). "Press Release: Alexander Gebauer Joins Executive Board of Omeicos Therapeutics and Named CEO and Chairman of Omeicos Ophthalmics". Berlin & Boston, MA.

		Record changed: 2020-04-26